Biotech Calendar: Key Dates for April
BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for April:
April 7
The U.S. Food and Drug Administration convenes an advisory panel to discuss
Forest Labs'
(FRX)
Daxas for chronic obstruction pulmonary disease. The FDA's briefing documents should be posted to the agency's web site on April 5.
April 8
Celgene
(CELG) - Get Report
analyst/investor day.
Lexicon Pharmaceuticals
(LXRX) - Get Report
analyst/investor day.
April 9
Cell Therapeutics
(CTIC) - Get Report
annual shareholders meeting.
April 10-17
American Academy of Neurology annual meeting. Data presentations expected from
Genzyme
( GENZ),
Acadia Pharmaceuticals
(ACAD) - Get Report
and
Acorda Therapeutics
(ACOR) - Get Report
, among others.
April 13-17
AMAG Pharmaceuticals
(AMAG) - Get Report
presents Feraheme data at National Kidney Foundation meeting.
April 14-18
European Association for the Study of the Liver (EASL) annual meeting. Hepatitis C data expected from
Vertex Pharmaceuticals
(VRTX) - Get Report
,
Idenix Pharmaceuticals
(IDIX)
,
Pharmasset
(VRUS)
and
Anadys
( ANDS), among others.
April 17-21
American Association for Cancer Research annual meeting. Data presentations expected from
Cyclacel Pharmaceuticals
(CYCC) - Get Report
,
Dendreon
(DNDN)
and
Peregrine Pharmaceuticals
(PPHM)
, among others.
April 18
FDA approval decision date for
OSI Pharmaceuticals'
( OSIP) Tarceva in first-line non-small cell lung cancer.
April 22
FDA convenes advisory panel to review
Acura Pharmaceuticals'
(ACUR)
abuse-resistant pain drug Acurox.
April 23
FDA approval decision date for Cell Therapeutics' pixantrone for non-Hodgkin's lymphoma.
April 30
FDA approval decision date for
Pozen's
(POZN)
pain drug Vimovo.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on
.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
